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presented model provides an opportunity to simulate burden in speciﬁc age bands, 
population burden, change in burden due to vaccination, and the seasonal/long-term 
cost effectiveness of vaccination with/out accounting for indirect protection effects. 
This study was sponsored by MedImmune.
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OBJECTIVES: Estimating the possibility of preventing pneumococcal illnesses by 
vaccination of infants with the 7-valent serum is realized with decision tree based 
models as “State of the Art”. A new network of models introducing the possibility of 
1) Comparing and validating the different approaches in a qualitative and quantitative 
way with each other, and 2) improving the capacity of simulation with dynamical 
behavior, structural insights and extended sensitivity analysis. METHODS: Based on 
a Markovian-Model from literature [1] the system was re- implemented and validated 
with the given data set. Starting with this model, results for Austrian data were com-
puted. After this an ODE was implemented as a “transponder” model, validated with 
the Markovian-Model and extended by dynamical behavior. In parallel an Agent 
Based model was implemented, validated with the transponder model and extended 
by individual agent behavior to simulate herd immunity and serotype replacement. 
RESULTS: Models can be adapted comfortably to additional data or new structural 
information; the approach is complex due to the fact that dynamic behavior can be 
represented and still ﬂexible for adapting to different scenarios; the model has modular 
structure, as population dynamics, illness and economical effects are modelled in dif-
ferent modules, which can be exchanged if necessary; and outcomes are comparable 
to each other in a qualitative and quantitative way. CONCLUSIONS: Results in the 
ﬁnal version of the agent based simulation vary from the starting model signiﬁcant. 
The reasons for the changes are described and can be followed step by step as all 
models are White-Box-Models and therefore can be re-simulated with given data. The 
Agent Based Model is identiﬁed as more realistic simulation of real behavior. Refer-
ence: [1] McIntosh, et al: The cost-burden of paediatric pneumococcal disease in the 
UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal 
conjugate vaccine.
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OBJECTIVES: Recently the Dutch government started immunizing Dutch girls with 
the human papillomavirus (HPV)-vaccine. Implementation of HPV-vaccination was 
controversial because different health-economic studies have estimated that the incre-
mental cost-effectiveness ratios (ICER) of HPV-vaccination were just below or above 
the informal Dutch cost-effectiveness threshold. In the Netherlands, there are no dif-
ferences in pharmacoeconomic guidelines and acceptable ICERs for vaccines and 
pharmacotherapies. It has recently been proposed that vaccines might warrant a dif-
ferent approach in estimating, interpreting and valuing the ICER. One of the aspects 
considered relates to the discount rate. In this study, we estimated the impact of dif-
ferent discount rates and approaches for discounting the health beneﬁts of HPV-
 vaccination. METHODS: A previously developed HPV Markov model was used to 
estimate the impact of discounting on the ICER of HPV-vaccination, with the discount 
rate for health beneﬁts ranging from -4% to 4%. Besides the discount rate, the impact 
of two different discounting methods was estimated. The ﬁrst method has been speciﬁ-
cally developed for infectious diseases, and proposes that health gains should be dis-
counted from the moment of risk reduction (averted HPV infection). The second 
method uses proportional discounting, which implies that the discount rate decreases 
over time. RESULTS: When we estimated the ICER of HPV-vaccination according to 
the Dutch guidelines, we found an ICER of a18,400/QALY. Ranging the discount rate 
from 4% to 4% resulted in an estimated ICER of a680 and a84,200 per QALY, 
respectively. Applying both alternative models resulted in ICERs of a12,800 and 
a8,960 per QALY, respectively. CONCLUSIONS: As expected, the exact discount 
rate and the underlying model for discounting have a considerable impact on the ICER 
of HPV-vaccination. The use of different discounting methodologies for vaccination, 
in comparison with therapeutic interventions, might provide a more realistic estima-
tion of future health beneﬁts for vaccination strategies and result in more favorable 
ICER values.
PODIUM SESSION IV: COST STUDIES
CO1
ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF 
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OBJECTIVE: To address the common issue of incomplete follow-up data in cost-
 effective analysis, we compared the actual average cumulative medical costs with the 
estimated costs using a set of statistical methodologies applicable to censored cost 
data. METHODS: A study cohort with monthly recorded concomitant medication 
costs was selected from the population of a randomised clinical trial. Among a total 
of 70 subjects, a pattern of 25% non-informative censoring was applied prior to the 
endpoint of interest (the ﬁrst event between death and 1-year follow-up visit). Statisti-
cal methods applied to deal with censored data included naïve estimators from com-
plete case analysis (CCA) and available-case analysis (ACA), as well as Lin’s, 
inverse-weighted and regression-based multiple-time-interval estimators. The covariate 
considered in regression models was continuous variable age. Bootstrapping with 
10,000 replications was used to obtain the standard deviation (SD). RESULTS: The 
actual average total cost per subject was £268.7 (SD: £52.0). Estimations from the 5 
methods given by mean (SD) were: CCA: £467.7 (£110.8), ACA: £246.0 (£49.8), Lin’s 
estimator: £301.6 (£60.6), inverse-weighted estimator: £294.5 (£15.6), regression-
based method: £245.5 (£49.2). CONCLUSIONS: By ignoring subjects with incom-
plete cost data, CCA overestimated the average cumulative cost as subjects with 
shorter survival tend to cumulate higher costs. Lin’s and inverse-weighted non-para-
metric estimators that make no assumption for the distribution of cost data slightly 
overestimated the average total cost. Regression-based method gave better results for 
both mean and SD than one-sample estimators (Lin’s and inverse-weighted) as it 
considered one cost-related factor (age) as covariate. The multiple-time-interval strate-
gies (Lin’s, inverse-weighted and regression-based) effectively assess cost information 
from censored subjects by treating them as uncensored in some of the time intervals. 
However, in this situation, small-size dataset and light censoring make ACA the best 
estimator.
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Hoyle M
University of Exeter, Exeter, Devon, UK
OBJECTIVES: Economic evaluations of health technologies typically assume constant 
real drug prices and model only the cohort of patients currently eligible for treatment. 
It has recently been suggested that in the UK, we should assume that real drug prices 
decrease at 4% p.a., and in New Zealand, that real drug prices decrease at 2% p.a. 
and at patent expiry, the drug price falls. It has also recently been suggested that we 
should model cohorts of patients starting treatment in the future. In this paper, the 
cost-effectiveness of drugs is modelled based on these ideas. METHODS: Algebraic 
expressions are developed to capture all costs and beneﬁts over the entire life cycle of 
a new drug. The lifetime of a new drug in the UK, a key model parameter, is estimated 
as 33 years, based on the historical lifetime of drugs in England over the last 27 years. 
Cost-effectiveness is calculated for seven new drugs recently appraised in the UK. 
RESULTS: Under the proposed methodology, all seven drugs appear far more cost-
effective in the UK than published. For example, the incremental cost-effectiveness 
ratio decreases by 45%, from £31,100 to £17,000 / QALY, for imatinib versus inter-
feron-a for chronic myeloid leukemia. CONCLUSIONS: The “life cycle correction 
factor” is introduced, which is used to convert estimates of cost-effectiveness as 
traditionally calculated into estimates under the proposed methodology. Under the 
methodology, all drugs in the UK and New Zealand appear more cost-effective, many 
far more cost-effective. Therefore, I suggest that the willingness to pay threshold 
should be reduced in the UK and New Zealand. The ranking of cost-effectiveness 
will change with drugs assessed as relatively more cost-effective and medical devices 
and surgical procedures relatively less cost-effective than previously thought. The 
methodology is very simple to implement and should be parameterized for other 
countries.
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OBJECTIVES: To assess work productivity loss among multiple sclerosis (MS) 
patients and the resulting indirect social cost due to MS from a real-world observa-
tional study. METHODS: ROBUST is a 12-month, US prospective, observational, 
open-label, single-arm, multi-center outcomes study of Interferon B-1b given every 
other day for relapsing forms of MS. For this analysis, baseline data from the Work 
Productivity and Activity Impairment questionnaire speciﬁc for MS (WPAI) were used. 
Productivity outcomes including absenteeism (work time missed), presenteeism 
(reduced on-the-job effectiveness) and overall work productivity loss were calculated 
from WPAI. Indirect social cost was estimated by modeling US national average wage 
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data by education level from the Bureau of Labor Statistics to the WPAI scores. Work 
productivity and indirect social cost were compared across patient sociodemographic 
characteristics and disease severity. RESULTS: A total of 191 MS patients were evalu-
ated at baseline with 114 working either full-time (78.1%) or part-time (21.9%). In 
this working sample, 75.4% were females, 72.8% were married, 71.1% were below 
50 years old and a majority were White (88.5%). The overall productivity loss due 
to MS among full-time employed patients and part-time employed patients was 42.5% 
(SD: 26.9) and 42.1% (SD: 30.6), respectively. This translates into a substantial pro-
ductivity loss of 17 hours of loss time in a 40-hour work-week for full-time workers 
and 8.4 hours of loss time in a 20-hour work week for part-time workers. At average 
wages, this productivity loss equates to an indirect annual social loss of $18,106 per 
patient (SD: $13,265) among full-time workers and $8,871 per patient (SD: $7,080) 
among part-time workers. Indirect social costs were signiﬁcantly correlated with 
increasing MS severity (r  0.21; p  0.0.029). CONCLUSIONS: Multiple sclerosis 
results in a substantial loss of work productivity among patients, which collectively 
results in signiﬁcant indirect social cost. The MS-related indirect social costs increase 
with increasing MS severity.
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OBJECTIVES: This study compares the result of cost estimation for glaucoma outpa-
tients using micro-costing and gross-costing methods. It also examines the factors 
contributing to the difference in results and investigates the impact of the result by 
costing method on Budget Impact Analysis(BIA). METHODS: Per year costs of glau-
coma outpatients were estimated for micro-costing, which consists of medical fee, eye 
examinations and laser therapy. A decision tree designed with 6 pathways was used. 
A patient’s visit frequency and transition probability for each pathway were obtained 
from literature and clinical expert opinions. In gross-costing, yearly per-capita outpa-
tient average costs were calculated by using health insurance statistics data on glau-
coma (ICD 10 code: H40). For BIA, each costing result was applied to the patients 
nationwide. RESULTS: The calculated costs of annual outpatient were $148.7 and 
$71.1 for micro-costing and gross-costing, respectively. The cost calculated by 
pathway in micro-costing ranged from the minimum of $142.9 to the maximum of 
$589.8. BIA result were $11,302,788 for micro-costing and $5,407,527 for gross-
costing. CONCLUSIONS: One factor contributing to the difference between the two 
methods is the gap between the standard model and the actual use of medical services. 
Another factor particular to gross-costing is that in the case a patient changes medical 
institutions, data from previous institutions do not accumulate, which underestimates 
the total cost of medical care. As a result, different costing methods may result in dif-
ferent decision-making of new drugs.
PODIUM SESSION IV: DIABETES STUDIES
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USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: 
POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH 
AND COMPLICATION RISK ESTIMATES
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Most previous work estimating survival rates for diabetes has been based on logistic 
regression or standardized ratios to derive odds ratios rather than being based on 
survival analysis with risk estimates over time. Few studies have estimated the excess 
risk between those with and without diabetes. OBJECTIVES: The purpose of this 
study was to estimate the excess risk and cumulative relative risks of death and com-
plications between those with newly diagnosed diabetes and those without. 
METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 and over were 
identiﬁed from the Ontario Diabetes Database and matched 1:2 using propensity 
scores with controls (non-diabetes cases). Using linked provincial administrative data-
bases, data on death and the following complications were recorded: myocardial 
infarction, stroke, angina, heart failure, blindness, amputation, nephropathy and cata-
ract. Kaplan Meier curves were calculated to estimate the probability of being event-
free for those with and without diabetes for up to 10 years of follow-up. RESULTS: 
A total of 610,852 patients aged 35 and over with diabetes were matched with 
1,221,704 patients without diabetes. For those with diabetes vs. those without, there 
was a statistically signiﬁcant increased relative risk at 10 years for death (1.417, [95%] 
CI 1.415–1.418), myocardial infarction (2.094, [95%] CI 2.092–2.095), stroke 
(1.877, [95%] CI 1.874–1.879), angina (1.526, [95%] CI 1.525–1.527), heart failure 
(2.520, [95%] CI 2.529–2.522), amputation (6.824, [95%] CI 6.823–6.824), 
nephropathy (2.902, [95%] CI 2.901–2.904), blindness (1.212, [95%] CI 1.205–
1.218) and cataract (1.326, [95%] CI 1.324–1.327). CONCLUSIONS: Diabetes 
is a signiﬁcant health problem with excess risk of death and complications typically 
associated with diabetes. Using estimates of risk of death or complications for a 
general (non-diseased) population can result in signiﬁcant underestimates of disease 
burden or cost-effectiveness in decision analytic models of disease management or 
prevention.
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OBJECTIVES: To assess the persistence of type-2 diabetic patients treated with basal 
supported oral therapy (BOT) with insulin glargine (GLA) compared to NPH insulin 
(NPH). METHODS: We performed a retrospective cohort study using claims data for 
ambulatory prescriptions within the German statutory health-insurance scheme, based 
on a representative sample of more than 80 % of German community pharmacies. 
Insulin-naive patients treated with oral antidiabetic drugs (OAD) who were addition-
ally initiating therapy with GLA or NPH between January 2003 and December 2006 
were included and followed up until December 2007. Persistence was deﬁned as the 
duration of time from initiation of GLA or NPH until switching to intensiﬁed con-
ventional insulin therapy (ICT). A switch to ICT was assumed whenever a short-acting 
insulin was prescribed for the ﬁrst time followed by at least one prescription of a 
long-acting insulin within six months. Univariate and multivariate Cox proportional 
hazards models were used to compare both cohorts. RESULTS: In total, 97,998 
patients (61,070 Glargine and 36,928 NPH) were included. Within the observation 
period, 23.5 % of GLA patients and 28.0 % of NPH patients switched to ICT. On 
average, these patients stayed 388 days on GLA and 313 days on NPH, respectively 
(p  0.001, log-rank test). The risk of switching to ICT was signiﬁcantly higher for 
NPH patients compared to GLA patients (unadjusted hazard ratio [HR] 1.34 (99 % 
CI: 1.29–1.38)). After adjustment for predeﬁned covariables i.e., type of physician 
(general practitioner vs. specialist), region, insurance status (member, family member, 
retired), health insurance company, comedication, number of OAD, dose of basal 
insulin, the risk for NPH patients remained signiﬁcantly higher (adjusted HR: 1.22 
(99 % CI: 1.18–1.27). CONCLUSIONS: Type 2 diabetic patients under basal sup-
ported oral therapy treated with insulin glargine stay signiﬁcantly longer on initial 
therapy until they switch to ICT when compared to NPH.
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OBJECTIVES: To assess the prevalence of potentially undiagnosed diabetes mellitus 
(UDM) in a nationally representative patient sample. METHODS: The data source 
was GE’s Medical Quality Improvement Consortium (MQIC) database (February 
2009) containing electronic medical record (EMR) data on 11 million patients in the 
U.S. Two previously published (Holt, et al, 2008) search strategies were applied to 
identify patients without diagnosis or medication evidence of DM, but with a fasting 
(FBG) or random blood glucose (RBG) result available (denominator for prevalence 
estimates). Strategy A patients were non-DM patients whose last glucose on record 
(LGOR)  RBG q11.1 or FBG q7.0 mmol/l. Strategy B patients were non-DM 
patients with LGOR (FBG or RBG) q7.0 mmol/l. Strategy A and B patients were each 
grouped by age/sex categories, and prevalence of UDM calculated. The time since 
LGOR to datacut date was also assessed. RESULTS: From 11,196,881 total patients, 
923,007 had diagnosed DM on record (n  570,723) or were presumed to have DM 
on the basis of prescribed oral hypoglycemics or insulin (n  352,284). After exclud-
ing additional patients with gestational diabetes and impaired glucose tolerance/pre-
diabetes,10,147,355 remained. Of these, 3,799,599 had a glucose result available, 
with 38,068 identiﬁed as possible UDM using Strategy A (prevalence 0.38%), and 
221,624 using Strategy B (prevalence 2.18%). In both instances, UDM prevalence 
increased with increasing age, in both sexes. Over 2 years had elapsed since the 
LGOR for over 50% of Strategy A patients, and 40% of Strategy B patients. 
CONCLUSIONS: The application of simple search algorithms to a large EMR data-
base suggests there may be substantial underdiagnosis of DM in the US general 
population.
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MANAGED CARE SETTING IN THE UNITED STATES
Sun SX1, Vallarino C2, Xu Y1, Kupfer S2, Bron M1
1Takeda Pharmaceuticals International, Inc, Deerﬁeld, IL, USA, 2Takeda Global Research and 
Development Center, Inc, Deerﬁeld, IL, USA
OBJECTIVES: To evaluate the risk of stroke or myocardial infarction (MI) in patients 
with type-2 diabetes mellitus (T2DM) receiving pioglitazone (PIO) or non-thiazolidin-
edione (Non-TZD) therapies. METHODS: A analysis of I3 Innovus database from 
January 1, 2000 to June 30, 2007 was conducted. T2DM patients (ICD-9 diagnosis 
codes 250.x0 or 250.x2) were grouped into PIO or Non-TZD cohorts based on the 
study drugs initiated. The index date is the ﬁrst dispensing of pioglitazone or Non-
TZD medications. Follow-up started at the index date and ended upon disenrollment 
from the health plan, ﬁrst occurrence of stroke or MI, or the end of the period, 
